Potent human monoclonal antibody for RSV prevention in people of all ages
Official title: Development of highly potent human monoclonal for RSV immunoprophylaxis
Funded at Mapp Biopharmaceutical, INC. · NIH-11472627 · Data updated 2026-11-12
A new one-dose monoclonal antibody (MBP002) is being developed to protect people from RSV, including infants, children, adults, and older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mapp Biopharmaceutical, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 24, 2025 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $993,435 |
| NIH project number | 5SB1AI191871-02 |
| Project ID | NIH-11472627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals across age groups from neonates to older adults who are at risk for severe RSV or reside in settings with high RSV exposure.
✕Less likely to help
Very young infants or individuals with specific medical conditions not addressed by this program may not benefit if the antibody does not work as intended or safety concerns arise.
What this research studies
This project aims to create a highly potent human monoclonal antibody that can be given in a single dose each RSV season to protect people from RSV infection. Researchers will work on optimizing MBP002 for safety and effectiveness in diverse age groups, including neonates, infants, children, adults, and the elderly. The study will involve laboratory development and testing to ensure the antibody works across different populations, with attention to real-world use and accessibility.
Why it matters
Potential benefit: If successful, MBP002 could provide a safe, affordable, and easy-to-use RSV preventive option for people of all ages, potentially reducing hospitalizations.
How similar studies have gone: Previous RSV monoclonal antibodies have shown reduced hospitalizations in high-risk groups, with ongoing development of long-acting options; this is a continuation toward broader protection.
Where this research is happening
-
Mapp Biopharmaceutical, INC.
San Diego, United States Active
Researchers
- Principal investigator: Monson, Ellen K — Mapp Biopharmaceutical, INC.
- Study coordinator: Monson, Ellen K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.